Most medtech due diligence stops at the financials. Vantage Biomedical Partners goes deeper — into the regulatory, clinical, and commercial risks that actually determine whether a medical device company will succeed or fail.

We provide specialized technical due diligence for medical devices and diagnostics, built around our proprietary 18-category risk framework covering FDA pathway analysis, predicate device strategy, clinical evidence assessment, reimbursement risk, manufacturing scalability, and quality system readiness.

Our team brings a rare combination of clinical, engineering, and industry perspectives:

Arvind Ravinutala, MD — Co-Founder. Physician executive serving as Medical Director, Associate Program Director, and P&T Committee Chair at Adventist Health. CMO at Fruit Street Health. SAB member at Spiro Medical ($67M raised). He brings the clinical and institutional decision-making lens that pure consultants lack.

Aswini Ravinutala — Co-Founder & CTO. Former Operations Manager at Axonics and Boston Scientific with deep expertise in design controls, quality systems, manufacturing operations, and product assurance. She evaluates medical devices from the perspective of someone who built them.

Rinda Sama — Senior Advisor. 30+ years in medtech commercialization leadership, including VP-level roles at Medtronic.

Whether you're evaluating an acquisition target, preparing for a 510(k), or raising your next round — Vantage gives you clarity before capital is deployed.

Vantage Biomedical Partners

Org chart

Teams

Offices

Vantage Biomedical Partners

Org chart

Teams

Offices

Related companies